Cargando…
Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)
PURPOSE: Cariprazine is a potent dopamine D(3)-preferring D(3)/D(2) receptor partial agonist in development for the treatment of schizophrenia, bipolar mania, and depression. Pharmacokinetics of cariprazine and the two clinically relevant metabolites (desmethyl- and didesmethyl-cariprazine) was eval...
Autores principales: | Nakamura, Tadakatsu, Kubota, Tomoko, Iwakaji, Atsushi, Imada, Masayoshi, Kapás, Margit, Morio, Yasunori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716719/ https://www.ncbi.nlm.nih.gov/pubmed/26834462 http://dx.doi.org/10.2147/DDDT.S95100 |
Ejemplares similares
-
PM513. Clinical Pharmacology Study of Cariprazine with Healthy Adult Japanese, Korean, Taiwanese, and Caucasian Male Subjects
por: Morio, Yasunori, et al.
Publicado: (2016) -
Population Pharmacokinetics of Cariprazine and its Major Metabolites
por: Periclou, Antonia, et al.
Publicado: (2020) -
Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
por: Periclou, Antonia, et al.
Publicado: (2019) -
Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023) -
Cariprazine hydrochloride for schizophrenia
Publicado: (2021)